Skip to content
Pfizer Logo

Pfizer: Update on Phase 3 CIFFRO Mini-Dystrophin Gene Therapy Trial

May 4, 2022
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Defeat Duchenne Canada is pleased to announce that regulatory authorities in Canada, along with the U.S., United Kingdom, Taiwan, Spain, and Belgium have approved the re-start of the Pfizer Phase 3 ambulatory trial (CIFFREO) for their investigational mini-dystrophin gene therapy for Duchenne muscular dystrophy. The timing on the re-start of the trials in Canada will be shared as soon as that information is available.

Click the button below to read the letter from Pfizer for the Duchenne community.

Related Articles